#China #Beijing #Lupin Limited #Oseltamivir #Yabao Pharmaceuticals

Lupin's Strategic Expansion into China

Lupin Limited, an eminent player in the global pharmaceutical industry, announced a significant achievement on May 22, 2026, with the approval of its Oseltamivir Phosphate oral suspension by China's National Medical Products Administration (NMPA). This landmark approval, in collaboration with Yabao Pharmaceuticals, positions Lupin as a crucial contender in the extensive and lucrative Chinese pharmaceutical market.

The Oseltamivir Phosphate suspension, designed with a concentration of 6 mg/mL, is particularly formulated for pediatric use, targeting children and infants. This product can be used not only for treating influenza A and B in patients aged two weeks and older but also for preventing the flu in those aged one year and older. The introduction of this medication highlights Lupin's commitment to addressing the needs of vulnerable populations, especially children susceptible to severe influenza complications.

Fabrice Egros, Lupin's President of Corporate Development, expressed his enthusiasm regarding this approval, recognizing it as a pivotal step in entering one of the world's largest and fastest-growing pharmaceutical markets. He stated, "We are delighted that we have received approval for Oseltamivir Oral Suspension in China. This is a strategic step in our entry into one of the world's largest pharmaceutical markets. It reflects our shared commitment to expanding access to high-quality, affordable therapies, particularly in pediatric care."

On the other hand, Wei Ren, the President of Yabao Pharmaceuticals, also emphasized the significance of this development. He noted that the official approval substantiates their partnership with Lupin and underscores Yabao's dedication to delivering high-quality pediatric medicines. He added, "We will further expand our R&D portfolio for pediatric and adult chronic disease drugs to jointly advance our businesses."

Lupin Limited is widely recognized for its extensive range of pharmaceutical offerings, including both branded and generic formulations as well as complex generics and biotechnology products. With products distributed across over 100 markets, it has built a robust reputation among healthcare professionals and consumers alike, primarily within therapeutic areas such as respiratory health, diabetes management, and women's health among others.

Founded in Mumbai, India, Lupin operates 15 state-of-the-art manufacturing facilities across various countries and maintains seven research centers globally. The company boasts a workforce exceeding 24,000 professionals, all dedicated to advancing public health through innovative and affordable medical solutions.

As Lupin embarks on this new journey into the Chinese market, its partnership with Yabao Pharmaceuticals—renowned for its specialization in pediatric medicine—will undoubtedly enhance the accessibility of vital medications to the Chinese population, particularly to its young children who are in urgent need of effective treatments for illnesses like influenza.

The strategic implications of this entry cannot be overstated: it signals Lupin's aspirations for greater international market presence, while reinforcing Yabao's standing in the pharmaceutical industry. As regulatory landscapes evolve and globalization in healthcare accelerates, collaborations like this exemplify the essential partnerships needed to fortify drug accessibility across varied demographics.

In conclusion, Lupin's approval for Oseltamivir Phosphate oral suspension marks not just a product launch but symbolizes a significant step forward in enhancing global health outcomes. It is a testament to the shared vision of both companies in promoting patient access to critical healthcare solutions across different aspects of health.